Related Experiment Video
Updated: Jan 14, 2026

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
Published on: January 24, 2025
The Role of Pharmacy Benefit Managers in Access to Biologics for Dermatologic Conditions
Melissa C Leeolou1, Justin L Jia1, Jason Harris2
1Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA.
Abstract:
In this commentary, we discuss the role of pharmacy benefit managers (PBMs) on access to biologics for patients with psoriasis. We highlight structural and system level barriers to biologics access, as well as how PBMs work as intermediaries between insurers, pharmacies, and drug manufactures to influence prescription formularies and generate health savings. We also discuss how controversial PBM practices such as step therapy, prior authorizations, and spread pricing may limit access to biologics and potentially increase cost for patients. Finally, we highlight how dermatologists and national organizations such as the National Psoriasis Foundation can collaborate and advocate for legislative reforms to increase transparency among PBMs.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Biopharmaceutics and Pharmacokinetics: Overview
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Bioequivalence: Overview

